Synribo

Chemical Nameomacetaxine mepesuccinate
Dosage FormInjection (subcutaneous; 3.5 mg)
Drug ClassAntineoplastics
SystemBlood
CompanyTeva Pharmaceuticals
Approval Year2012

Indication

  • For the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI)
Last updated on 4/22/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Synribo (omacetaxine mepesuccinate) Prescribing Information.2012Teva Pharmaceuticals USA Inc., North Wales, PA
Document TitleYearSource
Chronic myeloid leukemia, version 2.2021.2020Journal of the National Comprehensive Cancer Network